EIGR Eiger BioPharmaceuticals Inc.

-0.54  -4%
Previous Close 13.72
Open 13.73
Price To Book 7.45
Market Cap 251679033
Shares 19,095,526
Volume 59,796
Short Ratio
Av. Daily Volume 151,426

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released October 16, 2018 - endpoints met. Data to be presented at ENDO March 25, 2019.
Avexitide (Exendin 9-39)
Post-Bariatric Hypoglycemia (PBH)
Phase 2 LIMT positive data released October 17, 2018.
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
Phase 3 trial to be initiated 1Q 2019.
Chronic hepatitis delta virus (HDV)
Phase 2 trial did not meet endpoints - January 16, 2018.
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2 data released October 16, 2018 did not meet endpoints.
Ubenimex - ULTRA
Secondary lymphedema
Phase 2b negative data released April 2015. Formerly CLDN pre-merger
Ischemic or dilated cardiomyopathy
Phase 2 dosing to be completed mid-2019.
Pegylated interferon lambda + ritonavir (RTV)-boosted lonafarnib (LNF) - LIFT
Hepatitis delta virus (HDV)
NDA filing 2019.
Hutchinson-Gilford Progeria Syndrome (HGPS)

Latest News

  1. Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
  2. Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
  3. Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors
  4. Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech — New Horizons, Emerging Trends, and Upcoming Developments
  5. Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?
  6. Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
  7. Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
  8. Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection
  9. Eiger BioPharmaceuticals Reports on 2018 R&D Day
  10. Eiger BioPharmaceuticals to Host R&D Day in New York City
  11. The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
  12. Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer
  13. Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
  14. Eiger to Participate in Piper Jaffray Healthcare Conference
  15. Eiger BioPharma: 3Q Earnings Snapshot
  16. Eiger Bio Reports Third Quarter 2018 Financial Results
  17. Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
  18. The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares
  19. Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock